Every material Form 8-K IN8BIO, INC. has filed with the SEC since June 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IN8bio reported third quarter 2026 results on November 5, 2026. The net loss widened to $4.6 million from $3.9 million a year earlier, as research and development expenses rose to $2.6 million from $2.1 million, mainly due to preclinical costs for its T cell engager platform. Cash was $14.0 million at September 30, 2026, down from $27.1 million at December 31, 2025, and the company has no revenue reported in the filing, so shareholders face a higher loss and a shrinking cash balance.
Net loss of $4.6 million, or $0.24 per share, versus $3.9 million, or $0.85 per share, a year earlier
R&D expenses of $2.6 million versus $2.1 million, driven mainly by preclinical T cell engager costs
Cash of $14.0 million at September 30, 2026, versus $10.7 million a year earlier and $27.1 million at December 31, 2025
Company remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026
IN8bio reported second-quarter 2026 results, with a net loss of $4.8 million, or $0.25 per share, versus $5.1 million, or $1.24 per share, a year earlier. Cash was $18.0 million at June 30, 2026, up from $13.2 million a year earlier but down from $27.1 million at December 31, 2025, which shareholders should weigh against the company's continued cash needs.
Net loss of $4.8 million, or $0.25 per share, for the quarter ended June 30, 2026, compared with $5.1 million, or $1.24 per share, a year earlier
R&D expenses of $2.5 million were flat year over year; G&A expenses fell to $2.4 million from $2.7 million
Cash of $18.0 million at June 30, 2026, compared with $13.2 million a year earlier and $27.1 million at December 31, 2025
Weighted-average shares outstanding were 19,467,091 for the quarter, versus 4,119,153 a year earlier
IN8bio entered a Capital on Demand sales agreement with JonesTrading dated June 1, 2026, allowing it to sell new common stock from time to time at its discretion under an at-the-market program. It also terminated its prior Cantor Fitzgerald sales agreement, effective May 29, 2026, with no termination penalties, and the new program means the company can issue additional shares that could dilute existing holders.
New sales agreement with JonesTrading Institutional Services LLC dated June 1, 2026
JonesTrading commission is 3.0% of gross sales proceeds
Cantor Fitzgerald sales agreement from November 10, 2022 terminated effective May 29, 2026
Shares to be sold under Form S-3 registration statement (File No. 333-291393)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IN8BIO, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →